Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer
Journal: Nature
Author: Furong Huang et al., USA
A programmable RNA engineering platform restores immune recognition in prostate cancer, helping overcome tumor immune evasion and improve responses to immunotherapy.
AI-redesigned starting points and outcomes enhance protein evolution
Journal: Nature
Author: Nicholas A. Krasnow et al., USA
AI-designed protein starting points enabled scientists to evolve enzymes with greater stability, precision, and performance, accelerating the development of next-generation therapeutic proteins.
Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment
Journal: Cell Reports Medicine
Author: Tanvi Varadkar, Zhuoxin “Zora” Zhou et al., USA
A novel combination of targeted antibody-drug therapy and mitochondrial gene therapy nearly eliminated triple-negative breast tumors in preclinical models while boosting anti-cancer immunity.
Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer
Journal: Cancer Cell
Author: Courtney T.S. Kureshi et al., USA
A triple immunotherapy activated CD4+ T cells to eliminate pancreatic tumors in preclinical models, revealing a promising new strategy against treatment-resistant pancreatic cancer.
